LABCORP OFFERS TEST FOR DOSING COLORECTAL CANCER THERAPY

Laboratory Corporation of America Holdings has announced the availability of a test for genetic variants in the UGT1A1 gene associated with excessive toxicity in individuals treated with the late-stage colorectal cancer drug irinotecan hydrochloride (Camptosar).

In the U.S., colorectal cancer is the third most common cancer in men and women, affecting approximately 145,000 people each year. As many as 50 percent of those cases are metastatic and candidates for irinotecan-containing therapy, the company said.